

# SYNTHESES, CHARACTERIZATION, AND BIOLOGICAL ACTIVITY OF MIXED ANTIMALARIA METAL COMPLEXES

## ABSTRACT

This project deals with the synthesis, spectroscopic characterization and antimicrobial activity of metal complexes with Amodiaquine and pyrimethamine drugs. Five metal complexes derived from amodiaquine and pyrimethamine have been synthesized using the following metal ions: Co(II), Cu(II), Zn(II), Ni(II) and Fe(III). The complexes were characterized by decomposition temperature, solubility, conductivity measurement, elemental analyses, UV-Vis and IR spectroscopy. According to the results of physiochemical and spectroscopic data, the metal complexes were proposed to have the formula:  $[ML_1L_2].Y.xH_2O$  (where L = Ligand, M = Cu(II), Ni(II), Zn(II) and Fe(III), Y = SO<sub>4</sub> or Cl<sub>2</sub>).

The complexes have higher melting point than their free ligands and the lower value of conductivity test showed that the complexes are non-electrolytes. The spectroscopic data proposed that Amodiaquine coordinated through the oxygen atoms of the hydroxyl group, and pyrimethamine coordinated through Nitrogen atom of primary amine group. The complexes showed octahedral geometry with the ligands acting as bidentate.

The complexes were evaluated for *in vitro* antibacterial and antifungal activity against four isolates of *Staphylococcus faecalis*, *Escherichia coli*, *Klebsiella pneumoniae* and *Staphylococcus aureus*. The results show that the synthesized mixed ligands have higher antibacterial activities compared with the original ligands.

Keywords; Amodiaquine, Pyrimethamine, Mixed Antimalarial

## INTRODUCTION

In 2011, it was estimated that 3.3 billion people were at risk of malaria, with Africa bearing the brunt of the disease [1,2]. Approximately 80% of malaria cases and 90% of malaria-related deaths occur in Africa, disproportionately affecting children under five and pregnant women [3,4,5]. For decades, drug resistance in the malaria parasite *Plasmodium falciparum* has been a growing concern [6], with the potential for widespread resistance posing a significant public health risk [7], particularly given the lack of alternative antimalarial medicines expected to be available within the next five years [8,9,10]. This underscores the urgent need for the continued search for more affordable and effective compounds against these disease-causing organisms.

A major challenge in modern inorganic pharmaceutical chemistry is the development of safe and affordable drugs to combat malaria and antibiotic resistance [11]. While drug efficacy,

pharmacology, and toxicity are crucial in selecting compounds for development, efforts to standardize antimalarial and antibiotic drug efficacy studies remain limited [12,13,14]. The significance of metal complexes in medicine cannot be overstated; transition metals not only facilitate synthesis but also enhance drug delivery [15]. The unique properties of metal complexes offer distinct advantages in the discovery and development of new drugs.

### Mechanism of Action of Amodiaquine

Its mechanism of action is thought to be similar to CQ [16], but this is very controversial. Amodiaquine is a relatively wide compound closely related to chloroquine. In any case, Amodiaquine is as viable as chloroquine and is powerful against some chloroquine-resistant strains, even though protection from amodiaquine has been accounted for [17,18]. The mode of action of amodiaquine has not been determined. The structure of amodiaquine is shown below.




Fig 1: Chemical structure of amodiaquine

### 1.5.2 Pyrimethamine

#### Pharmacodynamics of Pyrimethamine.

“Pyrimethamine is one of the folic acid antagonist that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis” [19,20]. “It is used for the treatment of toxoplasmosis and acute malaria; For the prevention of malaria in areas non-resistant to pyrimethamine” [21]. It has molecular formula  $C_{12}H_{13}N_4$  with IUPAC name 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine. It is an antiparasitic compound used as an adjunct in the treatment of uncomplicated, chloroquine resistant *P. falciparum* malaria. Being a folic acid antagonist its rationale for therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursor involved in growth [22,23,24], hence it becomes highly selective against

plasmodia and *Toxoplasma gondii*. Pyrimethamine possesses tissue schizonticidal and blood schizonticidal activity against malaria parasites of humans [25]. “The action of pyrimethamine against *Toxoplasma gondii* is greatly enhanced when combined with sulfonamides” [26,27]. “It is primarily active against *Plasmodium falciparum*, but also against *Plasmodium vivax*. Due to the emergence of pyrimethamine-resistant strains of *P. falciparum*, pyrimethamine alone is seldom used now” [28,29].




Fig 2. Structure of Pyrimethamine

This study focuses on the synthesis and characterization of mixed antimalarial metal complexes, contributing to the ongoing efforts to discover novel antimalarial drugs that can effectively address the problem of drug resistance. The objectives of this research work are to;

i) Synthesize mixed transition metal complex of Amodiaquine, and pyrimethamine (an antimalarial drug) (ii) Characterize the resultant compounds using both the physical and spectroscopic properties such as solubility, melting point, conductivity, Ultraviolet-Visible and infrared spectroscopy, magnetic susceptibility and elemental analysis. (iii) Evaluate their biological potency by determining the antimicrobial properties of the complexes against some organisms such as *Streptococcus faecalis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Asperigellus niger* and *Candida albican*.


## 2. Methodology

All solvents and chemicals used in this research work are of quality analytical grade obtained from commercial dealers in Ilorin. The solvents used are Methanol, Ethanol, Chloroform, Ethyl Acetate. The metal salts are obtained from the Chemistry Department, University of Ilorin and they are; Cobalt (II) chloride hexahydrate [CoCl<sub>2</sub>.6H<sub>2</sub>O], Copper nitrate trihydrate [Cu(NO<sub>3</sub>)<sub>2</sub>.3H<sub>2</sub>O], Iron (II) sulphate heptahydrate [FeSO<sub>4</sub>.7H<sub>2</sub>O], *Nickel nitrate* hexahydrate [Ni(NO<sub>3</sub>)<sub>2</sub>.6H<sub>2</sub>O], and Zinc nitrate hexahydrate [Zn(NO<sub>3</sub>)<sub>2</sub>.6H<sub>2</sub>O].

The drugs used for this research work are obtained from May, Joy, Tuyill and Baker Pharmaceutical Industries Nigeria Plc. They are: L1 Amodiaquine and L2 Pyrimethamine

## 2.1 General procedure to synthesized the Metal Complex

Using the procedure carried out by Obaleye et al., [30]. A metal salt (1 mmol) was dissolved in 10 mL of ethanol in a round bottom flask. 1mmol of the L1 was mixed with 1mmol of L2 in a beaker. The mixed ligand was dissolved in 5ml Acetone and 5ml ethanol and added to the solution of the corresponding metal salt previously dissolved in 10ml ethanol in a round bottom flask. The solution was allowed to reflux with constant stirring for about 5 hours. The complexes thus formed were filtered, washed with ethanol to remove unreacted ligands, and then dried. The precipitate formed was filtered, washed, and dried in a vacuum. The mixed ligand metal complexes were prepared according to Equation 1.



where M is the metal ions, AMD is Amodiaquine which is (L1) and PRY is Pyrimethamine (L2)

## 2.2 Antimicrobial Studies

The antibacterial activities of the ligands and the metal complexes were carried out using a well diffusion method described in the literature by Lautre *et al.*, The nutrient agar medium and 5mm diameter Whatman No1 paper disc were used. The compounds were dissolved in DMSO at 50 and 100ppm concentrations. The filter paper was soaked in different compounds solutions, allowed to dry and then placed in petri dishes previously seeded with the test organisms. The plates were incubated for 24-30 hours at 37°C and the inhibition zone around each disc was measured in mm using zone reader. Using DMSO as control the average zone of inhibition was determined from the readings that will be taken in duplicate.

The bacteria species used in the test include standard strain of *Streptococcus faecalis* *Escherichia coli* *Klebsiella pneumoniae* *Staphylococcus aureus*. The antibacterial activity of the compounds was estimated based on the size of the inhibition zone formed around the wells on the seeded nutrient agar.

The antifungal activity of the ligands and the metal complexes was determined using the culture of two fungi species. They are *Asperigellus niger* *Candida albican* . They will be cultured on potato dextrose agar. The fungal culture will be incubated at 37°C for 38 hours before use.

## 3.0 RESULT AND DISCUSSION

In the present study shows the feasibility and justification for the synthesis of mixed antimicrobial metal complexes using amodiaquine and pyrimethamine as ligands. Five metal complexes of

Cu(II), Fe(III), Ni(II), Co(II) and Zn(II) ion have been successfully synthesized and characterized by spectral and analytical data.

### Solubility of the Ligand and Complexes

Table 1: Result of Solubility of the ligand and Drug-metal complexes

| Complexes/Ligand  | Distilled H <sub>2</sub> O |    | Methanol |    | Ethanol |    | Acetone |    |
|---|----------------------------|----|----------|----|---------|----|---------|----|
|   | C                          | H  | C        | H  | C       | H  | C       | H  |
| <b>Amodiaquine</b>  | NS                         | NS | NS       | S  | NS      | S  | NS      | S  |
| <b>Pyrimethamine</b>  | NS                         | NS | NS       | S  | NS      | S  | SS      | S  |
| <b>Cu(Amd)(Pry)Cl<sub>2</sub>.6H<sub>2</sub>O</b>               | NS                         | NS | NS       | NS | NS      | S  | S       | SS |
| <b>Co(Amd)(Pry)Cl<sub>2</sub>.6H<sub>2</sub>O</b>               | NS                         | NS | NS       | SS | NS      | SS | S       | S  |
| <b>Zn(Amd)(Pry)(NO<sub>3</sub>)<sub>2</sub>.7H<sub>2</sub>O</b> | NS                         | NS | NS       | SS | NS      | SS | S       | SS |
| <b>Ni(Amd)(Pry)(NO<sub>3</sub>)<sub>2</sub>.6H<sub>2</sub>O</b> | NS                         | NS | NS       | S  | NS      | S  | S       | S  |
| <b>Fe(Amd)(Pry)SO<sub>4</sub>.7H<sub>2</sub>O</b>               | NS                         | NS | NS       | SS | NS      | SS | S       | S  |

Key: C-Cold, H-Hot, NS-Not soluble, SS-Sparingly Soluble and S-Soluble

### Melting point and Conductivity of the Ligand and Complexes

Table 2: Result of physical properties, melting point, conductivity

| COMPOUND  | Colour | Melting point (°c) | Conductivity (S/m) |
|---|--------|--------------------|--------------------|
| <b>Amodiaquine</b>  | Yellow | 176.7              | 0.56               |
| <b>Pyrimethamine</b>  | White  | 240.8              | 0.04               |
| <b>Cu(Amd)(Pry)Cl<sub>2</sub>.6H<sub>2</sub>O</b>               | Blue   | 201.7              | 0.01               |
| <b>Co(Amd)(Pry)Cl<sub>2</sub>.6H<sub>2</sub>O</b>               | Brown  | 249.5              | 0.11               |
| <b>Zn(Amd)(Pry)(NO<sub>3</sub>)<sub>2</sub>.7H<sub>2</sub>O</b> | Cream  | 279.9              | 0.03               |
| <b>Ni(Amd)(Pry)(NO<sub>3</sub>)<sub>2</sub>.6H<sub>2</sub>O</b> | Green  | 191.2              | 0.32               |
| <b>Fe(Amd)(Pry)SO<sub>4</sub>.7H<sub>2</sub>O</b>               | Brown  | 105.7              | 0.41               |

The colour of the complexes varied ranging from yellowish to green and brown, from white to cream. The complexes also showed variable solubility in different solvents used, but they were generally soluble in Dimethylsulfoxide (DMSO). Some melting points of the mixed complexes were found to be higher compared to the free ligands.

Some of the complexes are powdery while some are crystalline. The result of the conductivity test of the complexes showed that they were non-electrolytes. Some of the complexes have a high percentage yield.

### 3.1 IR Spectral Studies

The infrared spectra of the complexes in the far IR region  $4,000 - 500 \text{ cm}^{-1}$  were compared with those of the ligands as shown in Fig 3-7. The infra-red spectra of the complexes were found to be different from those of the ligand and showed either a shift or disappearance of some characteristic frequencies and the appearance of some new band. The band of OH in the region  $3418.94 \text{ cm}^{-1}$  in the ligand was conspicuously absent in the complexes which suggest they are coordinating at the region.

The assignments were carried out by comparison of the IR spectra of the ligands with their complexes. The absorption region at  $3468.13 \text{ cm}^{-1}$  assigned to broad N-H in the free ligand has been shifted to a higher frequency in regions of  $3358 \text{ cm}^{-1}$ ,  $3306 \text{ cm}^{-1}$ ,  $3306 \text{ cm}^{-1}$ ,  $3431 \text{ cm}^{-1}$  and  $3429 \text{ cm}^{-1}$  coupled with a reduction in intensity ranging from medium to broadband.

However, the strong band at  $1627 \text{ cm}^{-1}$  has been shifted to the most intense band at  $1641 \text{ cm}^{-1}$ ,  $1639 \text{ cm}^{-1}$ ,  $1614 \text{ cm}^{-1}$  and  $1620 \text{ cm}^{-1}$ , which is assigned to the stretching frequency,  $\nu (-C=N)$ , of the azomethine ( $-CH=N$ ) group of Amodiaquine and pyrimethamine respectively.

Also, the infrared spectra display medium bands at  $653.89 \text{ cm}^{-1}$ ,  $532.37 \text{ cm}^{-1}$ ,  $601.81 \text{ cm}^{-1}$ , and  $665.46 \text{ cm}^{-1}$  attributed to M-L vibration. The water molecules present were confirmed to be coordinated through the metal ion.




Fig 3: Spectra of  $\text{FeSO}_4 + \text{Amd} + \text{Pry}$




Fig 4: Spectra of Zn(NO<sub>3</sub>)<sub>2</sub>+Amd+Pry




Fig 5: Spectra of CoCl<sub>2</sub>+Amd+Pry




Fig 6: Spectra of CuCl<sub>2</sub>+Amd+Pry




Fig 7: Spectra of Ni(NO<sub>3</sub>)<sub>2</sub>+Amd+Pry

### 3.2 UV- Visible Spectra

Table 3: UV-Visible Spectra of mixed metal complexes of Amodiaquine and Pyrimethamine

| COMPOUND   | Wavelength (nm) | Energies $\text{cm}^{-1}$ | Assignment                            |
|--|-----------------|---------------------------|---------------------------------------|
| Amodiaquine  | 205             | 48973                     | $\pi$ - $\pi^*$                       |
|  | 325             | 30890                     | n - $\pi^*$                           |
|  | 364             | 27497                     | n - $\pi^*$                           |
| Pyrimethamine  | 272             | 36798                     | $\pi$ - $\pi^*$                       |
| Cu(Amd)(Pry)Cl <sub>2</sub> .6H <sub>2</sub> O                 | 205             | 48973                     | $\pi$ - $\pi^*$                       |
|  | 328             | 30515                     | n - $\pi^*$                           |
| Co(Amd)(Pry)Cl <sub>2</sub> .6H <sub>2</sub> O                 | 280             | 35747                     | $\pi$ - $\pi^*$                       |
|  | 415             | 24118                     | $^4T_{1g} \rightarrow ^4A_{2g}$       |
|  | 529             | 18921                     | $^4T_{1g} \rightarrow ^4A_{2g}$       |
| Zn(Amd)(Pry)(NO <sub>3</sub> ) <sub>2</sub> .7H <sub>2</sub> O | 276             | 36265                     | $\pi$ - $\pi^*$                       |
|  | 363             | 27573                     | n - $\pi^*$                           |
| Ni(Amd)(Pry)(NO <sub>3</sub> ) <sub>2</sub> .6H <sub>2</sub> O | 408             | 24532                     | $^3A_{2g}(F) \rightarrow ^3T_{1g}(P)$ |
|  | 684             | 14633                     | $^3A_{2g}(F) \rightarrow ^3T_{1g}(F)$ |
| Fe(Amd)(Pry)SO <sub>4</sub> .7H <sub>2</sub> O                 | 446             | 22442                     | $^6A_{1g} \rightarrow ^4T_{1g}(G)$    |
|  | 781             | 12816                     | $^6A_{1g} \rightarrow ^4T_{2g}(G)$    |

The electronic absorption data of the ligands and the metal complexes in Table 3 above. Copper complexes showed two absorption bands at 205 and 328 nm. However, the bands were observed to have undergone a bathochromic shift in the metal complexes due to complexation. The electronic transition of Cobalt complex shows the bands at 280, 415 and a broad band at 529 nm corresponding to  $\pi$ -  $\pi^*$ ,  $^4T_{1g} \rightarrow ^4A_{2g}$ ,  $^4T_{1g} \rightarrow ^4A_{2g}$  transition, respectively. The band at 486 nm is expected for d-d transition of Co(II) complex [32]. The broadness of the band could be attributed to the overlapping of several bands as a result of the strong Jahn-Teller distortion expected in a d<sup>9</sup> ion [31].

## Mixed metal complexes Amodiaquine and Pyrimethamine




Fig 4: Proposed Structure of metal complexes of Amodiaquine and Pyrimethamine

Where M= Ni, Cu, Zn, Co and Fe<sup>2+</sup>

### 3.3 Antibacterial and Antifungal metal complexes of mixed Amodiaquine and pyrimethamine

The antibacterial activity of Amodiaquine, pyrimethamine and synthesized complexes are presented in table 4. They were screened against *Streptococcus fecalis*, *Escherichia coli*, *Klebsiella pneumonia*, *Staphylococcus aureus*. The solvent used was DMSO, the control exhibits no antimicrobial activity against the test micro-organisms and the activities was measured as function of zone of inhibition (mm). The result shows a remarkable contribution by the increase in the inhibition against some strains of bacterial and fungi

Table 4: Antimicrobial result for metal complexes of amodiaquine and pyrimethamine mm

| COMPLEXES  | <i>Streptococcus fecalis</i> | <i>Escherichia coli</i> | <i>Klebsiella pneumoniae</i> | <i>Staphylococcus aureus</i> |
|--|------------------------------|-------------------------|------------------------------|------------------------------|
| Amodiaquine  | 09                           | 10                      | 20                           | 15                           |
| Pyrimethamine  | 15                           | 10                      | -                            | 13                           |
| Cu(Amd)(Pry)Cl <sub>2</sub> .6H <sub>2</sub> O                 | 30                           | 20                      | 11                           | 25                           |
| Co(Amd)(Pry)Cl <sub>2</sub> .6H <sub>2</sub> O                 | 14                           | 15                      | -                            | 13                           |
| Zn(Amd)(Pry)(NO <sub>3</sub> ) <sub>2</sub> .7H <sub>2</sub> O | 11                           | 16                      | 16                           | 10                           |
| Ni(Amd)(Pry)(NO <sub>3</sub> ) <sub>2</sub> .6H <sub>2</sub> O | 25                           | 17                      | -                            | -                            |

|  |   |    |   |   |
|--|---|----|---|---|
| Fe(Amd)(Pry)SO <sub>4</sub> .7H <sub>2</sub> O | - | 15 | - | - |
|--|---|----|---|---|

Table 5: Anti-Fungi result for metal complexes of amodiaquine and pyrimethamine (mm)

| Compound   | <i>Aspergillus niger</i> | <i>Candida albican</i> |
|--|--------------------------|------------------------|
| Amodiaquine  | 15                       | 13                     |
| Pyrimethamine  | 16                       | -                      |
| Cu(Amd)(Pry)Cl <sub>2</sub> .6H <sub>2</sub> O                 | 25                       | 12                     |
| Co(Amd)(Pry)Cl <sub>2</sub> .6H <sub>2</sub> O                 | 09                       | -                      |
| Zn(Amd)(Pry)(NO <sub>3</sub> ) <sub>2</sub> .7H <sub>2</sub> O | -                        | 11                     |
| Ni(Amd)(Pry)(NO <sub>3</sub> ) <sub>2</sub> .6H <sub>2</sub> O | 10                       | -                      |
| Fe(Amd)(Pry)SO <sub>4</sub> .7H <sub>2</sub> O                 | 13                       | -                      |

### 3.4 CONCLUSION

Reviews on anti-malarial drugs have shown that there are three consistent ways in which we believe antimalarial drug resistance emerges. Spontaneous drug-resistant mutations have affected the effectiveness of direct drug treatment [33,34]. Therefore, it is important to recognize the possibility of considering metal drugs as potential therapeutic agents. The present study shows the feasibility and justification for the synthesis of mixed antimicrobial metal complexes using amodiaquine and pyrimethamine as ligands. The metal complexes of Cu(II), Fe(III), Ni(II), Co(II) and Zn(II) ion have been successfully synthesized and characterized by spectral and analytical data.

Based on these data, octahedral geometry has been assigned to the complexes. In the complexes, pyrimethamine was proposed to coordinate through N atom of the primary amine group, amodiaquine coordinated through the O atom of the hydroxyl group. However, from the analytical data obtained, the complexes possessed better physical properties as compared to the free ligands.

The antimicrobial results indicate that the complexes showed milder effects as chemotherapy agents than their parent drugs. Therefore, they could be more effective against *Plasmodium falciparum* than the parent drugs.

### DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declares that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during the writing or editing of manuscripts.

## REFERENCES

- [1]. Maigemu, A. Y., & Hassan, K. R. H. (2015). Malaria as a cause of morbidity and mortality: A socio-economic overview. *Research on humanities and social sciences*, 5(8).
- [2]. Afolabi, B. M. (2017). Predictable impact of current economic recession on the spread and severity of diseases in African countries: Focus on Nigeria. *Journal of Preventive Information Continental*, 3(1), 1-11.
- [3]. Kogan, F., & Kogan, F. (2020). Malaria burden. *Remote Sensing for Malaria: Monitoring and Predicting Malaria from Operational Satellites*, 15-41.
- [4]. World Health Organization. A rapid dipstick antigen capture assay for the diagnosis of falciparum malaria. WHO informal consultation on recent advances in diagnostic techniques and vaccines for malaria. *Bulletin of the World Health Organization* 2016 ; 74:47–54
- [5]. Oladimeji, K. E., Tsoka-Gwegweni, J. M., Ojewole, E., & Yunga, S. T. (2019). Knowledge of malaria prevention among pregnant women and non-pregnant mothers of children aged under 5 years in Ibadan, South West Nigeria. *Malaria journal*, 18, 1-12.
- [6]. Thu, A. M., Phyto, A. P., Landier, J., Parker, D. M., & Nosten, F. H. (2017). Combating multidrug-resistant Plasmodium falciparum malaria. *The FEBS journal*, 284(16), 2569-2578.
- [7]. Sibley, C. H. (2014). Understanding drug resistance in malaria parasites: basic science for public health. *Molecular and biochemical parasitology*, 195(2), 107-114.
- [8]. Wells, T. N., Alonso, P. L., & Gutteridge, W. E. (2017). New medicines to improve control and contribute to the eradication of malaria. *Nature reviews Drug discovery*, 8(11), 879-891.
- [9]. Olliaro, P., & Wells, T. N. C. (2015). The global portfolio of new antimalarial medicines under development. *Clinical Pharmacology & Therapeutics*, 85(6), 584-595.
- [10]. Burrows, J. N., Hooft van Huijsduijnen, R., Möhrle, J. J., Oeuvray, C., & Wells, T. N. (2014). Designing the next generation of medicines for malaria control and eradication. *Malaria journal*, 12, 1-20.

- [11]. Khan, S. T., Musarrat, J., & Al-Khedhairy, A. A. (2016). Countering drug resistance, infectious diseases, and sepsis using metal and metal oxides nanoparticles: current status. *Colloids and Surfaces B: Biointerfaces*, 146, 70-83.
- [12]. Sinha, S., Sarma, P., Sehgal, R., & Medhi, B. (2017). Development in assay methods for in vitro antimalarial drug efficacy testing: a systematic review. *Frontiers in pharmacology*, 8, 754.
- [13]. Aguiar, A. C. C., da Rocha, E. M., de Souza, N. B., França, T. C., & Krettli, A. U. (2018). New approaches in antimalarial drug discovery and development: a review. *Memorias do Instituto Oswaldo Cruz*, 107, 831-845.
- [14]. Freitas, A. A., Nneji, P. O., Oluchi, O. L., Tochi, N. S., Shine, G. K., Onuba, C. O., ... & Adedeji, O. (2019). Drug Sensitivity Pattern of Bacteria from Dental Extraction: A Microbiological Study. *International Journal of Research and Reports in Dentistry*, 7(2), 103-112.
- [15]. Rocha, E. P., & Danchin, A. (2014). An analysis of determinants of amino acids substitution rates in bacterial proteins. *Molecular biology and evolution*, 21(1), 108-116
- [16]. Biot, C., Taramelli, D., Forfar-Bares, I., Maciejewski, L. A., Boyce, M., Nowogrocki, G., ... & Egan, T. J. (2014). Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. *Molecular pharmaceutics*, 2(3), 185-193.
- [17]. O'Neill, P. M., Mukhtar, A., Stocks, P. A., Randle, L. E., Hindley, S., Ward, S. A., ... & Park, B. K. (2014). Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. *Journal of medicinal chemistry*, 46(23), 4933-4945.
- [18]. Holmgren, G. (2015). *Plasmodium falciparum resistance to amodiaquine in monotherapy and combination therapy with artesunate*. Karolinska Institutet (Sweden).
- [19]. Ben-Harari, R. R., Goodwin, E., & Casoy, J. (2017). Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review. *Drugs in R&D*, 17, 523-544.
- [20]. Antczak, M., Dzitko, K., & Długońska, H. (2016). Human toxoplasmosis—Searching for novel chemotherapeutics. *Biomedicine & Pharmacotherapy*, 82, 677-684.
- [21]. Cooper, E., & O'Hare, B. A. M. (2014). Infections in children. *International Maternal and Child Hospital Health Care*.
- [22]. Tucker, M. S. (2016). *Phenotypic and genotypic analysis of in vitro selected artemisinin resistant Plasmodium falciparum*. University of South Florida.
- [23]. Shahinas, D. (2017). *Targeting Plasmodium falciparum heat shock protein 90 (pfhsp90): a strategy to reverse antimalarial resistance* (Doctoral dissertation, University of Toronto).

- [24]. Sabnis, Y. A. (2014). *Modeling, design, and synthesis of parasitic cysteine protease inhibitors*. The University of Mississippi.
- [25]. Efferth, T., Romero, M. R., Bilia, A. R., Osman, A. G., ElSohly, M., Wink, M., ... & Marin, J. J. (2016). Expanding the therapeutic spectrum of artemisinin: Activity against infectious diseases beyond malaria and novel pharmaceutical developments. *World Journal of Traditional Chinese Medicine*, 2(2), 1-23.
- [26]. Martins-Duarte, É. S., de Souza, W., & Vommaro, R. C. (2014). Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model. *Experimental parasitology*, 133(3), 294-299.
- [27]. Antczak, M., Dzitko, K., & Długońska, H. (2016). Human toxoplasmosis—Searching for novel chemotherapeutics. *Biomedicine & Pharmacotherapy*, 82, 677-684.
- [28]. Thompson, P. (2012). *Antimalarial agents: chemistry and pharmacology* (Vol. 12). Elsevier.
- [29]. Ringwald, P., Shallick, L., Miller, J. M., Seiber, E., & World Health Organization. (2015). *Susceptibility of Plasmodium falciparum to antimalarial drugs: report on global monitoring 1996-2004* (No. WHO/MAL/2005.1103). World Health Organization.
- [30]. Obaleye, Joshua A., Johnson F. Adediji, Ebenezer T. Olayinka, and Matthew A. Adebayo. "Synthesis, antimicrobial potential and toxicological activities of Ni (II) complex of mefloquine hydrochloride." *Res. Pharm. Biotech* 1 (2016): 9-15.
- [31]. Ajibade, P. A., & Kolawole, G. A. (2018). Synthesis, characterization and antiprotozoal studies of some metal complexes of antimalarial drugs. *Transition metal chemistry*, 33, 493-497.
- [32]. Summers, K. L. (2019). A structural chemistry perspective on the antimalarial properties of thiosemicarbazone metal complexes. *Mini Reviews in Medicinal Chemistry*, 19(7), 569-590.
- [33]. Shah, N. K., & Valecha, N. (2016). Antimalarial drug resistance. *Advances in Malaria Research*, 383-407.
- [34]. AL Blackie, M. (2014). Metal containing chloroquinolines: beyond hit and miss antimalarial efficacy to solid science. *Mini Reviews in Medicinal Chemistry*, 13(4), 597-606..